TORONTO--(BUSINESS WIRE)--ArcticDx, Inc. announced that its Vita RiskTM pharmacogenetic analysis, which supports the genotype-directed selection of appropriate eye vitamin therapies for patients suffering from age-related macular degeneration (AMD), will be available as part of the new Macula Risk® PGx test launched at the ASRS meeting. The Vita RiskTM analysis leverages the latest evidence-based medicine to provide a recommendation of zinc alone, antioxidants plus zinc, or antioxidants alone to tested patients based on the treatment that demonstrated the greatest benefit (reduction in the incidence of advanced AMD at 12 years) in an analysis of 995 patients from the AREDS dataset with moderate AMD in at least one eye.
“This data demonstrates that the composition of supplements recommended to AMD patients should be guided by an individual’s genetic risk profile, indicating a clear role for genetic testing in clinical management.”
The Age-Related Eye Disease Study (AREDS) demonstrated that high-dose supplementation with antioxidants plus zinc decreased the risk of progression to advanced AMD in patients with moderate to severe disease in one eye. A recently unveiled pharmacogenetic analysis of this dataset, titled “CFH and ARMS2 genetic polymorphisms predict response to antioxidants and zinc in patients with age-related macular degeneration“ (Ophthalmology 2013, in press), showed that components within the AREDS formulation may be beneficial or deleterious based on a patient’s genetic profile, and that 49% of the patients studied would have derived more benefit from a treatment regimen other than the AREDS formulation. Authors of the study also estimated that genotype-directed therapy of the AREDS study population would have more than doubled the reduction in AMD progression rate compared with treatment with the AREDS formulation.
“Genotype-directed nutritional therapy could result in significantly improved outcomes for many patients with moderate AMD,” suggests “CFH and ARMS2” first author Carl C. Awh, MD, of Tennessee Retina. Additionally, co-author Ivana K. Kim, MD, of Massachusetts Eye and Ear Infirmary, notes that “This data demonstrates that the composition of supplements recommended to AMD patients should be guided by an individual’s genetic risk profile, indicating a clear role for genetic testing in clinical management."
About Macula Risk® PGx
The Macula Risk® PGx test is a combined prognostic and pharmacogenetic DNA test intended for patients with a diagnosis of early or intermediate AMD. In addition to providing a novel pharmacogenetic vitamin recommendation, Macula Risk® PGx also predicts a patient’s risk of progression to advanced AMD within 2, 5 and 10 years using an analysis of AMD genes, clinical AMD status, and significant non-genetic risk factors. The Macula Risk® PGx test incorporates 15 genetic variants (SNPs) on 12 genes across 4 major biologic pathways.
About Age-Related Macular Degeneration (AMD)
The incidence of AMD grows from 1 in 10 people over the age of 60 to more than 1 in 4 people over the age of 75. Most people do not know they have AMD until they start to lose central vision in one eye. Vision loss can happen quickly and without warning; with current treatment, it may be arrested, and in some cases, improved. Early detection and treatment of AMD is critical for the prevention of blindness; accordingly, frequent monitoring is recommended for ‘at risk’ patients.
ArcticDx Inc. is a molecular diagnostic company with expertise in the design, development and commercialization of validated prognostic and pharmacogenetic tests for significant diseases including age-related macular degeneration (AMD). Our business model is focused towards the rapid commercialization of Intellectual Property (IP) from international gene discovery programs. Arctic combines the work of academic strategic partners (i.e., Cancer Care Ontario, University of Cambridge, University of Michigan, and University of Regensberg) with our international commercialization processes to bring the latest research in molecular diagnostics to healthcare providers.